A detailed history of Casdin Capital, LLC transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Casdin Capital, LLC holds 5,617,599 shares of RVMD stock, worth $215 Million. This represents 14.62% of its overall portfolio holdings.

Number of Shares
5,617,599
Previous 5,714,775 1.7%
Holding current value
$215 Million
Previous $164 Million 10.47%
% of portfolio
14.62%
Previous 17.17%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$26.56 - $33.55 $2.58 Million - $3.26 Million
-97,176 Reduced 1.7%
5,617,599 $181 Million
Q4 2023

Feb 14, 2024

BUY
$18.35 - $34.12 $71.7 Million - $133 Million
3,904,775 Added 215.73%
5,714,775 $164 Million
Q1 2023

May 15, 2023

SELL
$20.76 - $30.09 $14.8 Million - $21.5 Million
-715,000 Reduced 28.32%
1,810,000 $39.2 Million
Q4 2022

Feb 14, 2023

BUY
$17.68 - $25.53 $47,736 - $68,931
2,700 Added 0.11%
2,525,000 $60.1 Million
Q3 2022

Nov 14, 2022

BUY
$17.46 - $26.0 $2.66 Million - $3.96 Million
152,300 Added 6.43%
2,522,300 $49.7 Million
Q4 2021

Feb 14, 2022

SELL
$24.35 - $33.7 $10.5 Million - $14.5 Million
-430,000 Reduced 15.36%
2,370,000 $59.7 Million
Q3 2021

Nov 15, 2021

BUY
$23.95 - $33.41 $11.9 Million - $16.5 Million
495,000 Added 21.48%
2,800,000 $77 Million
Q2 2021

Aug 16, 2021

BUY
$29.0 - $47.44 $13.4 Million - $21.8 Million
460,465 Added 24.96%
2,305,000 $73.2 Million
Q1 2021

May 17, 2021

BUY
$37.21 - $54.43 $7.81 Million - $11.4 Million
210,000 Added 12.85%
1,844,535 $84.6 Million
Q3 2020

Nov 16, 2020

BUY
$22.61 - $34.8 $6.78 Million - $10.4 Million
299,999 Added 22.48%
1,634,535 $56.9 Million
Q2 2020

Aug 14, 2020

BUY
$19.65 - $39.34 $294,750 - $590,100
15,000 Added 1.14%
1,334,536 $42.1 Million
Q1 2020

May 15, 2020

BUY
$20.0 - $34.08 $26.4 Million - $45 Million
1,319,536 New
1,319,536 $28.9 Million

Others Institutions Holding RVMD

About Revolution Medicines, Inc.


  • Ticker RVMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,697,600
  • Market Cap $3.36B
  • Description
  • Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...
More about RVMD
Track This Portfolio

Track Casdin Capital, LLC Portfolio

Follow Casdin Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Casdin Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Casdin Capital, LLC with notifications on news.